Global Fecal Calprotectin Test Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Gastrointestinal Disorders
![]() |
Fecal Calprotectin Test Market |
The global Fecal Calprotectin Test market is
estimated to be valued at US$ 140.61
Million In 2023 and is expected to exhibit a CAGR Of 10.8% over the forecast period 2023-2030, as highlighted in
a new report published by Coherent Market Insights.
Market Overview:
Fecal calprotectin test is a noninvasive diagnostic tool for assessing the
severity of intestinal inflammation. It measures the levels of calprotectin, a
protein found in high concentrations in neutrophils, in stool samples. This
test is commonly used to differentiate between inflammatory bowel disease (IBD)
and irritable bowel syndrome (IBS), as well as to monitor the response to
treatment in patients with IBD. The advantages of the fecal calprotectin test
include its simplicity, cost-effectiveness, and accurate results, making it an
essential tool for gastroenterologists and other healthcare professionals.
Market Key Trends:
One key trend driving the growth of the Fecal
Calprotectin Test Market is the increasing prevalence of
gastrointestinal disorders. Inflammatory bowel diseases, such as Crohn's
disease and ulcerative colitis, are on the rise worldwide. According to the
Centers for Disease Control and Prevention (CDC) and the Crohn's & Colitis
Foundation, approximately 3 million adults in the United States have been
diagnosed with IBD. Additionally, the Global Burden of Disease study estimates
that the global prevalence of IBD has increased by 18.7% from 1990 to 2017. The
fecal calprotectin test plays a crucial role in the diagnosis and management of
these disorders, thus driving the demand for this market.
PEST Analysis:
Political: The political landscape can impact the fecal calprotectin test
market through government regulations and policies regarding healthcare
accessibility and reimbursement. For example, favorable reimbursement policies
for diagnostic tests can drive market growth.
Economic: The economic factors that can influence the market include healthcare
spending capacity, insurance coverage, and overall economic stability, as these
factors can affect patient access to medical tests.
Social: Societal factors such as an aging population, changing lifestyles, and
awareness about gastrointestinal disorders can contribute to the demand for
fecal calprotectin tests.
Technological: Technological advancements in diagnostic testing, such as the
development of high-sensitivity immunoassays and point-of-care testing
solutions, can drive market growth by improving the accuracy and convenience of
fecal calprotectin tests.
D) Key Takeaways:
Paragraph 1: The global fecal calprotectin test market is expected to witness
high growth, exhibiting a CAGR of 10.8% over the forecast period, due to
increasing prevalence of gastrointestinal disorders. The rising number of
inflammatory bowel disease cases and the need for accurate diagnostic tools are
key drivers for market growth.
Paragraph 2: In terms of regional analysis, North America is expected to be the
fastest-growing and dominating region in the fecal calprotectin test market.
This can be attributed to the high prevalence of inflammatory bowel diseases in
this region, along with advanced healthcare infrastructure and reimbursement
policies.
Paragraph 3: Key players operating in the global fecal calprotectin test market
include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F.
Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv
Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc.,
RayBiotech, Inc., and ALPCO. These players are involved in strategic
initiatives such as partnerships, collaborations, and product launches to
strengthen their market presence and expand their product portfolio.
In conclusion, the global fecal calprotectin test market is poised for
significant growth due to the increasing prevalence of gastrointestinal
disorders. The fecal calprotectin test offers a noninvasive and efficient
diagnostic tool for healthcare professionals, and advancements in technology
are further driving market growth. North America is expected to be the dominant
region in the market, with key players actively contributing to its growth
through strategic initiatives.
Comments
Post a Comment